ARID1A and urinary bladder carcinoma: For various bladder cancer cell lines with ARID1A-truncating mutations or shRNA-mediated depletion, our experiments revealed that EZH2 inhibition is synthetically lethal for bladder cancer cells with ARID1A deficiency.